Maven Securities’s Core Laboratories CLB Stock Holding History

Maven Securities’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,822	Closed	-$52K	–	1094
2021 Q1	$52K	Buy	+1,822	New	+$62.2K	﹤0.01%	1079

Other funds holding CLB

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

AKO Capital London, United Kingdom $4.29B AUM 4.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Maven Securities's CLB Position: Q2 2021 in Review

Maven Securities sold out of Core Laboratories (CLB) in Q2 2021, closing a stake of 1,822 shares — an estimated $52K sold.

Maven Securities first reported a position in CLB in Q1 2021 and held it in 1 quarter. The position peaked at $52K in Q1 2021. 195 funds tracked by Wall St. Rank hold CLB as of Q2 2021.

Maven Securities reported no remaining Core Laboratories position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 1,822 Core Laboratories shares in Q2 2021, an estimated $52K.
Maven Securities first reported a position in Core Laboratories in Q1 2021 and held it in 1 quarter.
Maven Securities's Core Laboratories position peaked at $52K in Q1 2021.
195 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.